Table Info

Table 1.

Drug dosing schedule for induction and inhibition of necroptosis

Drugs	Induction		Inhibition		Target
Drugs	Dose	Time	Dose	Time	Target
Z-VAD-fmk	20 µM	24 Hrs	20 µM	24 Hrs	Pan caspase inhibitor
Necrostatin-1	-	-	30 µM	24 Hrs	RIPK-1 inhibitor
BV-6	10 ng	24 Hrs	10 ng	24 Hrs	Pan cIAPs and xIAPs inhibitor
TNF-α	10 ng	12 Hrs	10 ng	12 Hrs	Necroptosis inducer, TNFR

RIPK-1: receptor interacting protein kinase; cIAPs: cellular inhibitor of apoptosis proteins; xIAPs: X-linked inhibitor of apoptosis proteins; TNFR: tumor necrosis factor receptor

Supplementary materials

The supplementary figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/1003194_sup_1.pdf.

Declarations

Author contributions

BT, AD, and AKR: Data curation, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing—original draft. RV: Software, Validation, Visualization, Methodology, Writing—original draft. YK and AB: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing—review & editing.

Conflicts of interest

The authors declare that there is no conflict of interest involved.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Datasets are available on request: The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

The authors acknowledge the funding support provided by PGIMER for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Linkermann A, Stockwell BR, Krautwald S, Anders H. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. 2014;14:759–67. [DOI] [PubMed]

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541. [DOI] [PubMed] [PMC]

Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112–9. [DOI] [PubMed]

Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008;135:1161–3. [DOI] [PubMed]

Thakur B, Kumar Y, Bhatia A. Programmed necrosis and its role in management of breast cancer. Pathol Res Pract. 2019;215:152652. [DOI] [PubMed]

Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res. 2014;16:204. [DOI] [PubMed] [PMC]

Krysko O, Aaes TL, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4:e631. [DOI] [PubMed] [PMC]

Sangiuliano B, Pérez NM, Moreira DF, Belizário JE. Cell death-associated molecular-pattern molecules: inflammatory signaling and control. Mediators Inflamm. 2014;2014:821043. [DOI] [PubMed] [PMC]

Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, et al. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol. 2015;6:402. [DOI] [PubMed] [PMC]

10.

Vrakas CN, O’Sullivan RM, Evans SE, Ingram DA, Jones CB, Phuong T, et al. The Measure of DAMPs and a role for S100A8 in recruiting suppressor cells in breast cancer lung metastasis. Immunol Invest. 2015;44:174–88. [DOI] [PubMed]

11.

Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014;21:69–78. [DOI] [PubMed] [PMC]

12.

Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112. [DOI] [PubMed]

13.

Thakur B, Saha L, Bhatia A. Relative refractoriness of breast cancer cells to tumour necrosis factor-α induced necroptosis. Clin Exp Pharmacol Physiol. 2022;49:1294–306. [DOI] [PubMed]

14.

Thakur B, Saha L, Dahiya D, Bhatia A. Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer. J Basic Clin Physiol Pharmacol. 2022;34:91–102. [DOI] [PubMed]

15.

Lee K, Lee H, Han D, Moon WK, Kim K, Oh HJ, et al. Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. Breast Cancer Res. 2020;22:130. [DOI] [PubMed] [PMC]

16.

Lalaoui N, Merino D, Giner G, Vaillant F, Chau D, Liu L, et al. Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death Differ. 2020;27:2768–80. [DOI] [PubMed] [PMC]

17.

Thakur B, Verma R, Bhatia A. Mutations in Necroptosis-Related Genes Reported in Breast Cancer: A Cosmic and Uniport Database-Based Study. Clin Breast Cancer. 2024;S1526–820900356–2. [DOI] [PubMed]

18.

Koo G, Morgan MJ, Lee D, Kim W, Yoon J, Koo JS, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015;25:707–25. [DOI] [PubMed] [PMC]

19.

Khorsandi L, Orazizadeh M, Niazvand F, Abbaspour MR, Mansouri E, Khodadadi A. Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. Bratisl Lek Listy. 2017;118:123–8. [DOI] [PubMed]

20.

Shahsavari Z, Karami-Tehrani F, Salami S. Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7. Anticancer Agents Med Chem. 2018;18:245–54. [DOI] [PubMed]

21.

Murao A, Aziz M, Wang H, Brenner M, Wang P. Release mechanisms of major DAMPs. Apoptosis. 2021;26:152–62. [DOI] [PubMed] [PMC]

22.

Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and Damage-Associated Molecular Patterns (DAMPs). Am J Transplant. 2016;16:3338–61. [DOI] [PubMed]

23.

Denning N, Aziz M, Gurien SD, Wang P. DAMPs and NETs in Sepsis. Front Immunol. 2019;10:2536. [DOI] [PubMed] [PMC]

24.

Wu Chuang A, Kepp O, Kroemer G, Bezu L. Endoplasmic reticulum stress in the cellular release of damage-associated molecular patterns. Int Rev Cell Mol Biol. 2020;350:1–28. [DOI] [PubMed]

25.

Rigiracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, et al. Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression. Cancers (Basel). 2021;13:645. [DOI] [PubMed] [PMC]

26.

Cai Z, Zhang A, Choksi S, Li W, Li T, Zhang X, et al. Activation of cell-surface proteases promotes necroptosis, inflammation and cell migration. Cell Res. 2016;26:886–900. [DOI] [PubMed] [PMC]

27.

Zhang X, Yin M, Zhang L. Keratin 6, 16 and 17-Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis. Cells. 2019;8:807. [DOI] [PubMed] [PMC]

28.

Díaz-Ramos A, Roig-Borrellas A, García-Melero A, López-Alemany R. α-Enolase, a multifunctional protein: its role on pathophysiological situations. J Biomed Biotechnol. 2012;2012:156795. [DOI] [PubMed] [PMC]

29.

Tu S, Chang C, Chen C, Tam K, Wang Y, Lee C, et al. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121:539–53. [DOI] [PubMed]

30.

Seny Dd, Cobraiville G, Charlier E, Neuville S, Lutteri L, Goff CL, et al. Apolipoprotein-A1 as a damage-associated molecular patterns protein in osteoarthritis: ex vivo and in vitro pro-inflammatory properties. PLoS One. 2015;10:e0122904. [DOI] [PubMed] [PMC]

31.

Kang N, Ji Z, Li Y, Gao J, Wu X, Zhang X, et al. Metabolite-derived damage-associated molecular patterns in immunological diseases. FEBS J. 2024;291:2051–67. [DOI] [PubMed]

32.

Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114:2367–74. [DOI] [PubMed]

33.

Wang H, Kim SJ, Lei Y, Wang S, Wang H, Huang H, et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther. 2024;9:235. [DOI] [PubMed] [PMC]

34.

Ahrens S, Zelenay S, Sancho D, Hanč P, Kjær S, Feest C, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36:635–45. [DOI] [PubMed]

35.

Zhang JG, Czabotar PE, Policheni AN, Caminschi I, Wan SS, Kitsoulis S, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36:646–57. [DOI] [PubMed]

36.

Nami B, Wang Z. Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. Cancers (Basel). 2018;10:274. [DOI] [PubMed] [PMC]

37.

Xia L, Xiao X, Liu WL, Song Y, Liu TJJ, Li YJ, et al. Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling. Oncogene. 2018;37:323–31. [DOI] [PubMed]

38.

Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, López-Muñoz E, Guillén N, Olivo-Marin J, et al. Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Front Oncol. 2019;9:943. [DOI] [PubMed] [PMC]

39.

Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012;2012:283181. [DOI] [PubMed] [PMC]

40.

Calaf GM, Abarca-Quinones J. Ras protein expression as a marker for breast cancer. Oncol Lett. 2016;11:3637–42. [DOI] [PubMed] [PMC]

41.

Zhang W, Wang M, Ji C, Liu X, Gu B, Dong T. Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials. Biomed Pharmacother. 2024;177:116930. [DOI] [PubMed]

42.

Fagone P, Rosa MD, Palumbo M, Gregorio CD, Nicoletti F, Malaguarnera L. Modulation of heat shock proteins during macrophage differentiation. Inflamm Res. 2012;61:1131–9. [DOI] [PubMed]

43.

Fearing BV, Dyke MEV. In vitro response of macrophage polarization to a keratin biomaterial. Acta Biomater. 2014;10:3136–44. [DOI] [PubMed]

44.

Fréret M, Rottenberg P, Calbo S, Lequerré T, Vittecoq O. 08.02 Alpha-enolase promotes pro-inflammatory phenotype of monocytes-derived macrophages in vitro. Ann Rheum Dis. 2017;76:A75. [DOI]

45.

Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8:31. [DOI] [PubMed] [PMC]